ISAL 2019 | Learnings from a CAR-T center: leukapheresis, bridging therapy, toxicities & more

Michael von Bergwelt

Michael von Bergwelt, MD, PhD, of LMU Hospital Munich, Munich, Germany, discusses the considerations when giving CAR-T in the clinic, including reimbursement, preparing the patient, determining a bridging therapy, toxicity control and more. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video